Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2009

01.12.2009 | Research Paper

Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients

verfasst von: Fangwei Xie, Kun Li, Xuenong Ouyang

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

The transcription factor Twist plays a key role in cancer metastasis. The present study aimed at investigating clinical Twist expression in patients with esophageal squamous cell carcinoma (ESCC) in order to correlate the Twist levels with the patients’ survival rates and their other clinical parameters. Immunohistochemical staining using polyclonal Twist antibody was performed on paraffin embedded specimens of 112 ESCC patients and non-neoplastic esophageal epithelium used as a control. The overall staining intensity was analyzed along with clinicopathologic data and prognosis of ESCC. Twist expression was significantly higher in ESCC than in non-neoplastic oesophageal epithelium (P < 0.001). The Twist expression directly correlated with distant metastasis after esophagectomy (P = 0.001). Kaplan–Meier estimate in conjunction with the log-rank test revealed an inverse proportion relationship between postoperative survival rates of the patients and their Twist expression levels (log-rank, P < 0.001). In addition, Cox mono-variate analysis revealed that T/N classification, pTNM stage, distant metastasis and Twist expression were significantly correlated with mortality risk of patients after operation (P < 0.05). By Cox multi-variate analysis, Twist expression (risk ratio = 2.394; P < 0.001) and N classification were identified as the independent prognostic factors of patient survival. In conclusion, upregulated Twist expression in the primary ESCC significantly correlates with the high risk of subsequent development of distant metastasis and low postoperative survival rates; the latter was not significantly correlated with patients’ age, gender, tumor location and differentiation. Twist may serve as an independent prognostic marker for predicting development of distant metastasis in ESCC patients and their survival.
Literatur
1.
Zurück zum Zitat Jemal A, Thun MJ, Ries LAG et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefPubMed Jemal A, Thun MJ, Ries LAG et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefPubMed
2.
Zurück zum Zitat Wingo PA, Ries LA, Rosenberg HM et al (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207CrossRefPubMed Wingo PA, Ries LA, Rosenberg HM et al (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207CrossRefPubMed
3.
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE et al (2002) AJCC Cancer staging manual. Lippincott-Raven, Philadelphia Fleming ID, Cooper JS, Henson DE et al (2002) AJCC Cancer staging manual. Lippincott-Raven, Philadelphia
4.
Zurück zum Zitat Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMed Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMed
5.
Zurück zum Zitat Noguchi T, Kimura Y, Takeno S et al (2003) Chromosomal imbalance in esophageal squamous cell carcinoma: 3q gain correlates with tumor progression but not prognostic significance. Oncol Rep 10:1393–1400PubMed Noguchi T, Kimura Y, Takeno S et al (2003) Chromosomal imbalance in esophageal squamous cell carcinoma: 3q gain correlates with tumor progression but not prognostic significance. Oncol Rep 10:1393–1400PubMed
6.
Zurück zum Zitat Tabernero J, Macarulla T, Ramos FJ et al (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748CrossRefPubMed Tabernero J, Macarulla T, Ramos FJ et al (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748CrossRefPubMed
8.
Zurück zum Zitat Thisse B, Stoetzel C, El Messal M et al (1987) The Twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorso-ventral pattern. Nucleic Acids Res 15:3439–3453CrossRefPubMed Thisse B, Stoetzel C, El Messal M et al (1987) The Twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorso-ventral pattern. Nucleic Acids Res 15:3439–3453CrossRefPubMed
9.
Zurück zum Zitat Hüsemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68CrossRefPubMed Hüsemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68CrossRefPubMed
10.
Zurück zum Zitat Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMed Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMed
11.
Zurück zum Zitat Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552CrossRefPubMed Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552CrossRefPubMed
12.
Zurück zum Zitat Yuen HF, Chan YP, Wong ML et al (2007) Upregulation of Twist in esophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60:510–514CrossRefPubMed Yuen HF, Chan YP, Wong ML et al (2007) Upregulation of Twist in esophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60:510–514CrossRefPubMed
13.
Zurück zum Zitat Kajiyama H, Hosono S, Terauchi M et al (2006) Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 71:394–401CrossRefPubMed Kajiyama H, Hosono S, Terauchi M et al (2006) Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 71:394–401CrossRefPubMed
14.
Zurück zum Zitat Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376CrossRefPubMed Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376CrossRefPubMed
15.
Zurück zum Zitat Song LB, Liao WT, Mai HQ et al (2006) The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242:258–265CrossRefPubMed Song LB, Liao WT, Mai HQ et al (2006) The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 242:258–265CrossRefPubMed
16.
Zurück zum Zitat He P, Shi J, Chen W et al (2002) Multivariate analysis by Cox Proportional Hazards Model on prognoses of patients with bile duct carcinoma after resection. Chin Med J 115:1538–1541PubMed He P, Shi J, Chen W et al (2002) Multivariate analysis by Cox Proportional Hazards Model on prognoses of patients with bile duct carcinoma after resection. Chin Med J 115:1538–1541PubMed
17.
Zurück zum Zitat Hamilton SR, Aaltonen LA (2000) World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system. IARC Press, Lyon Hamilton SR, Aaltonen LA (2000) World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system. IARC Press, Lyon
18.
Zurück zum Zitat Cox DR (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–220 Cox DR (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–220
19.
Zurück zum Zitat Zhang Z, Xie D, Li X et al (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38:598–606CrossRefPubMed Zhang Z, Xie D, Li X et al (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38:598–606CrossRefPubMed
20.
Zurück zum Zitat Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A Twist for survival and cancer progression. Br J Cancer 94:13–17CrossRefPubMed Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A Twist for survival and cancer progression. Br J Cancer 94:13–17CrossRefPubMed
22.
Zurück zum Zitat Podsypanina K, Du YN, Jechlinger M et al (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841–1844CrossRefPubMed Podsypanina K, Du YN, Jechlinger M et al (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841–1844CrossRefPubMed
23.
Zurück zum Zitat Ansieau S, Bastid J, Doreau A et al (2008) Induction of EMT by Twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14:79–89CrossRefPubMed Ansieau S, Bastid J, Doreau A et al (2008) Induction of EMT by Twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14:79–89CrossRefPubMed
24.
Zurück zum Zitat Hoek K, Rimm DL, Williams KR et al (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270–5282CrossRefPubMed Hoek K, Rimm DL, Williams KR et al (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270–5282CrossRefPubMed
25.
Zurück zum Zitat Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939CrossRefPubMed Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939CrossRefPubMed
26.
Zurück zum Zitat Weinberg RA (2008) Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 14:283–284CrossRefPubMed Weinberg RA (2008) Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 14:283–284CrossRefPubMed
Metadaten
Titel
Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients
verfasst von
Fangwei Xie
Kun Li
Xuenong Ouyang
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2009
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9292-5

Weitere Artikel der Ausgabe 8/2009

Clinical & Experimental Metastasis 8/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.